Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases

Frontiers in Nuclear Medicine

Nuclear Medicine

Heloisa P. Soares¹  Gabriel C. Fine²  Nwanneka Okwundu³  Donald M. Cannon³  Christopher R. Weil³ 

[1] Department of Medical Oncology, University of Utah School of Medicine, Salt Lake City, UT, United States;Department of Nuclear Medicine, University of Utah, Salt Lake City, UT, United States;Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT, United States;

关键词: neuroendocrine tumor;    lutetium (177Lu)-DOTA-octreotat (DOTATATE);    central nervous system;    metastases;    peptide receptor radionuclide therapy (PRRT);   

DOI  :  10.3389/fnume.2023.1074948

 received in 2022-10-20, accepted in 2023-01-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

Neuroendocrine tumors (NETs) rarely metastasize to the brain. However, when they occur, NET brain metastases are associated with a poor prognosis. Due to their low incidence, NET brain metastases are poorly studied, with few data to guide a consensus for management. Prior reports have documented treatment with chemotherapy, resection, whole brain radiation therapy, and stereotactic radiosurgery, all with low rates of survival. We present a case of a patient with type 3 well-differentiated gastric NET with widespread metastatic disease, including central nervous system lesions in the pineal gland and left cerebellopontine angle (CPA), which were avid on 68Ga-dotatate positron emission tomography. The patient received four doses of 200 mCi (7.4 GBq) lutetium-177 oxodotreotide (177Lu-dotatate) administered every 8 weeks over the course of 6 months. The treatments provided local control of the pineal and CPA lesions for 23 months until the development of diffuse leptomeningeal progression that necessitated further therapies. 177Lu-dotatate may be a viable treatment for local control of NET brain metastases. More studies are needed to validate its efficacy in this clinical scenario.

【 授权许可】

Unknown   
© 2023 Okwundu, Weil, Soares, Fine and Cannon.